Korro Bio Inc has a consensus price target of $122.5 based on the ratings of 4 analysts. The high is $180 issued by Piper Sandler on March 27, 2024. The low is $90 issued by RBC Capital on March 27, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., BMO Capital, and HC Wainwright & Co. on May 21, 2024, May 15, 2024, and May 15, 2024, respectively. With an average price target of $106.67 between HC Wainwright & Co., BMO Capital, and HC Wainwright & Co., there's an implied 119.95% upside for Korro Bio Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/21/2024 | Buy Now | 106.2% | HC Wainwright & Co. | Mitchell Kapoor | → $100 | Reiterates | Buy → Buy | Get Alert |
05/15/2024 | Buy Now | 147.44% | BMO Capital | Kostas Biliouris | → $120 | Maintains | Outperform | Get Alert |
05/15/2024 | Buy Now | 106.2% | HC Wainwright & Co. | Mitchell Kapoor | $115 → $100 | Maintains | Buy | Get Alert |
03/28/2024 | Buy Now | 137.13% | HC Wainwright & Co. | Mitchell Kapoor | $100 → $115 | Maintains | Buy | Get Alert |
03/27/2024 | Buy Now | 271.16% | Piper Sandler | Yasmeen Rahimi | $180 → $180 | Maintains | Overweight | Get Alert |
03/27/2024 | Buy Now | 85.58% | RBC Capital | Luca Issi | $70 → $90 | Maintains | Outperform | Get Alert |
03/26/2024 | Buy Now | 147.44% | BMO Capital | Kostas Biliouris | $120 → $120 | Reiterates | Outperform → Outperform | Get Alert |
03/12/2024 | Buy Now | 44.34% | RBC Capital | Luca Issi | → $70 | Reiterates | Outperform → Outperform | Get Alert |
02/27/2024 | Buy Now | 147.44% | BMO Capital | Kostas Biliouris | → $120 | Initiates | → Outperform | Get Alert |
01/19/2024 | Buy Now | 106.2% | HC Wainwright & Co. | Mitchell Kapoor | → $100 | Reiterates | Buy → Buy | Get Alert |
12/04/2023 | Buy Now | 106.2% | HC Wainwright & Co. | Mitchell Kapoor | → $100 | Initiates | → Buy | Get Alert |
11/29/2023 | Buy Now | 44.34% | RBC Capital | Luca Issi | → $70 | Initiates | → Outperform | Get Alert |
11/10/2023 | Buy Now | 271.16% | Piper Sandler | Yasmeen Rahimi | → $180 | Initiates | → Overweight | Get Alert |
The latest price target for Korro Bio (NASDAQ:KRRO) was reported by HC Wainwright & Co. on May 21, 2024. The analyst firm set a price target for $100.00 expecting KRRO to rise to within 12 months (a possible 106.20% upside). 13 analyst firms have reported ratings in the last year.
The latest analyst rating for Korro Bio (NASDAQ:KRRO) was provided by HC Wainwright & Co., and Korro Bio reiterated their buy rating.
There is no last upgrade for Korro Bio
There is no last downgrade for Korro Bio.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Korro Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Korro Bio was filed on May 21, 2024 so you should expect the next rating to be made available sometime around May 21, 2025.
While ratings are subjective and will change, the latest Korro Bio (KRRO) rating was a reiterated with a price target of $100.00 to $100.00. The current price Korro Bio (KRRO) is trading at is $48.50, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.